title: Complete tumor response following intratumoral 32P BioSilicon on human hepatocellular and pancreatic carcinoma xenografts in nude mice.
abstract: OBJECTIVE
  32P BioSilicon is a new, implantable, radiological medical device that comprises particles of highly pure silicon encapsulating 32phosphorus (32P) for the treatment of unresectable solid tumors. Prior to administration, the device particles are suspended in a formulant which provides an even suspension of the intended dose for implantation. The primary objective of this animal trial study was to investigate the effects of intratumoral injection of 32)P BioSilicon on human hepatocellular (HepG2) and pancreatic carcinoma (2119) xenografts implanted in nude mice (BALB/c). A secondary objective was the histopathologic examination of the tumor foci and surrounding tissue during the study.
  
  
  METHODS
  Cultured human carcinoma cells (HepG2 and 2119) were injected s.c. into the gluteal region of nude mice. When the implanted tumors were approximately 1 cm in diameter, 32P BioSilicon (0.5, 1.0, and 2.0 MBq) or formulant was injected into the tumors. Implanted tumor size was measured once a week for 10 weeks. At study termination, the tumor and surrounding normal tissue were collected and fixed in 10% formalin and processed for histopathologic analysis.
  
  
  RESULTS
  32P BioSilicon produced a reduction in HepG2 tumor volume when compared with formulant control, and complete response was observed among tumors in the 1.0 and 2.0 MBq treatment groups after week 8. There was also significant reduction in 2119 tumor volume in all treated groups, with the complete response rate of 67% in the 2.0 MBq group.
  
  
  CONCLUSIONS
  32P BioSilicon suppressed the growth of both human hepatocellular and pancreatic carcinoma xenografts implanted in nude mice and complete responses were also observed in tumors at higher radiation doses.
authors.affiliation: Department of Experimental Surgery, Singapore General Hospital, Singapore.
authors.forename: Kai
authors.initials: K
authors.lastname: Zhang
authors.forename: Susan L E
authors.initials: SL
authors.lastname: Loong
authors.forename: Steve
authors.initials: S
authors.lastname: Connor
authors.forename: Sidney W K
authors.initials: SW
authors.lastname: Yu
authors.forename: Soo-Yong
authors.initials: SY
authors.lastname: Tan
authors.forename: Robert T H
authors.initials: RT
authors.lastname: Ng
authors.forename: Khai Mun
authors.initials: KM
authors.lastname: Lee
authors.forename: Leigh
authors.initials: L
authors.lastname: Canham
authors.forename: Pierce K H
authors.initials: PK
authors.lastname: Chow
mesh_terms: D000818:Animals; D001918:Brachytherapy / Q000295:instrumentation / Q000379:methods*; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000532:radiotherapy*; D045744:Cell Line, Tumor; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D008114:Liver Neoplasms, Experimental / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D010190:Pancreatic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use*; D012825:Silicon; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays / Q000379:methods*
chemical_list: D010761:Phosphorus Radioisotopes; D012825:Silicon